HomeCompareUBX vs EPRT

UBX vs EPRT: Dividend Comparison 2026

UBX yields 999.50% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UBX wins by $18762502.82M in total portfolio value
10 years
UBX
UBX
● Live price
999.50%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18762502.88M
Annual income
$15,677,048,250,727.08
Full UBX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — UBX vs EPRT

📍 UBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUBXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UBX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UBX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UBX
Annual income on $10K today (after 15% tax)
$84,957.52/yr
After 10yr DRIP, annual income (after tax)
$13,325,491,013,118.02/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, UBX beats the other by $13,325,491,002,203.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UBX + EPRT for your $10,000?

UBX: 50%EPRT: 50%
100% EPRT50/50100% UBX
Portfolio after 10yr
$9381251.47M
Annual income
$7,838,524,131,783.90/yr
Blended yield
83.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

UBX
Analyst Ratings
7
Buy
3
Hold
Consensus: Buy
Price Target
$2.50
+1149.4% upside vs current
Range: $1.00 — $4.00
Altman Z
-26.4
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UBX buys
0
EPRT buys
0
No recent congressional trades found for UBX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUBXEPRT
Forward yield999.50%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$18762502.88M$63.4K
Annual income after 10y$15,677,048,250,727.08$12,840.73
Total dividends collected$18526733.01M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$2.50$35.50

Year-by-year: UBX vs EPRT ($10,000, DRIP)

YearUBX PortfolioUBX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$110,650$99,950.02$11,205$505.18+$99.4KUBX
2$1,151,991$1,033,595.59$12,672$682.46+$1.14MUBX
3$11,289,539$10,056,908.06$14,490$930.48+$11.28MUBX
4$104,190,015$92,110,208.43$16,786$1,282.69+$104.17MUBX
5$905,946,717$794,463,401.71$19,753$1,791.56+$905.93MUBX
6$7,425,409,853$6,456,046,865.26$23,677$2,541.64+$7425.39MUBX
7$57,399,102,727$49,453,914,184.22$29,008$3,672.99+$57399.07MUBX
8$418,691,166,930$357,274,127,011.89$36,463$5,425.08+$418691.13MUBX
9$2,883,602,458,699$2,435,602,910,084.79$47,238$8,221.57+$2883602.41MUBX
10$18,762,502,881,535$15,677,048,250,727.08$63,385$12,840.73+$18762502.82MUBX

UBX vs EPRT: Complete Analysis 2026

UBXStock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Full UBX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this UBX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UBX vs SCHDUBX vs JEPIUBX vs OUBX vs KOUBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.